Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Completed Phase 2 Trials for Tacrolimus (DB00864)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00105001Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerTreatment